Molecular Medicine
TABLE OF CONTENTS
Volume 82, Issue 4 (October 2007)
Editorial |
News and Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
Contents
Contents
In this issue
Clin Pharmacol Ther 82: 341; doi:10.1038/sj.clpt.6100366
See also: Point/Counterpoint by CalfeeSee also: Point/Counterpoint by Kravitz & BellSee also: Commentary by WoodcockSee also: Article by Deverka et al. See also: Article by Tang et al. See also: Practice by GoldmanSee also: Ethics by EvansEditorial
Molecular Medicine Hones Therapeutic Arts to Science
S A Waldman, M R Terzic and A Terzic
Clin Pharmacol Ther 82: 343-347; doi:10.1038/sj.clpt.6100360
News and Views
Highlights
News and Views
Clin Pharmacol Ther 82: 348-349; doi:10.1038/sj.clpt.6100364
ASCPT News
ASCPT News
Clin Pharmacol Ther 82: 350-351; doi:10.1038/sj.clpt.6100365
Macroscopy
Nutraceuticals: Miracle or Meme?
M H T Ridinger
Clin Pharmacol Ther 82: 352-356; doi:10.1038/sj.clpt.6100354
Perspectives
Point/Counterpoint
An Assessment of Direct-to-Consumer Advertising of Prescription Drugs
J E Calfee
Clin Pharmacol Ther 82: 357-360; doi:10.1038/sj.clpt.6100353
Direct-to-Consumer Advertising of Prescription Drugs: Balancing Benefits and Risks, and a Way Forward
R L Kravitz and R A Bell
Clin Pharmacol Ther 82: 360-362; doi:10.1038/sj.clpt.6100348
Commentaries
Drug Discovery and Development in the Age of Molecular Medicine
P Vallance and M Levick
Clin Pharmacol Ther 82: 363-366; doi:10.1038/sj.clpt.6100333
Beyond Genomics
C T Dollery
Clin Pharmacol Ther 82: 366-370; doi:10.1038/sj.clpt.6100363
Targeting Cell Death
D J Hausenloy and L Scorrano
Clin Pharmacol Ther 82: 370-373; doi:10.1038/sj.clpt.6100352
Translation of Pharmacogenetics into Clinically Relevant Testing Modalities
L M Baudhuin, L J Langman and D J O'Kane
Clin Pharmacol Ther 82: 373-376; doi:10.1038/sj.clpt.6100350
Molecular Medicine: How, What, and When?
J Woodcock
Clin Pharmacol Ther 82: 376-378; doi:10.1038/sj.clpt.6100349
See also: Article by Deverka et al.Forum
Low Hepatic Cytochrome P450 3A Activity is a Risk for Corticosteroid-induced Osteonecrosis
A N Nafziger and J S Bertino Jr
Clin Pharmacol Ther 82: 379; advance online publication, February 28, 2007; doi:10.1038/sj.clpt.6100105
Response to Nafziger and Bertino
Y Kaneshiro and Y Oda
Clin Pharmacol Ther 82: 380; doi:10.1038/sj.clpt.6100323
State of the Art
State of the Art
Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed
C M Hartford and M J Ratain
Clin Pharmacol Ther 82: 381-388; advance online publication, August 29, 2007; doi:10.1038/sj.clpt.6100317
Research
Articles
The Effect of ABCB1 Polymorphism on the Pharmacokinetics of Saquinavir Alone and in Combination with Ritonavir
C J L la Porte, Y Li, L Béïque, B C Foster, B Chauhan, G E Garber, D W Cameron and R P G van Heeswijk
Clin Pharmacol Ther 82: 389-395; advance online publication, March 14, 2007; doi:10.1038/sj.clpt.6100157
G Protein 
3 Polymorphism and Triptan Response in Cluster Headache
M Schürks, T Kurth, P Stude, C Rimmbach, J de Jesus, M Jonjic, H-C Diener and D Rosskopf
Clin Pharmacol Ther 82: 396-401; advance online publication, March 14, 2007; doi:10.1038/sj.clpt.6100159
Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors
J Bouligand, A Le Maitre, D Valteau-Couanet, J Grill, L Drouard-Troalen, A Paci, O Hartmann, E Benhamou and G Vassal
Clin Pharmacol Ther 82: 402-409; advance online publication, March 28, 2007; doi:10.1038/sj.clpt.6100168
Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam
E D Kharasch, A Walker, N Isoherranen, C Hoffer, P Sheffels, K Thummel, D Whittington and D Ensign
Clin Pharmacol Ther 82: 410-426; advance online publication, June 6, 2007; doi:10.1038/sj.clpt.6100237
Integrating Molecular Medicine into the US Health-care System: Opportunities, Barriers, and Policy Challenges
P A Deverka, T Doksum and R J Carlson
Clin Pharmacol Ther 82: 427-434; advance online publication, August 8, 2007; doi:10.1038/sj.clpt.6100319
See also: Commentary by WoodcockPolymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy
Z Tang, M A Diamond, J-M Chen, T A Holly, R O Bonow, A Dasgupta, T Hyslop, A Purzycki, J Wagner, D M McNamara, T Kukulski, S Wos, E J Velazquez, K Ardlie and A M Feldman
Clin Pharmacol Ther 82: 435-440; advance online publication, August 29, 2007; doi:10.1038/sj.clpt.6100331
Discovery & Development
Discovery
The Paracrine Hormone Hypothesis of Colorectal Cancer
G M Pitari, P Li, J E Lin, D Zuzga, A V Gibbons, A E Snook, S Schulz and S A Waldman
Clin Pharmacol Ther 82: 441-447; advance online publication, August 8, 2007; doi:10.1038/sj.clpt.6100325
Development
Derivation of GMP Raw Materials for Use in Regenerative Medicine: hESC-based Therapies, Progress Toward Clinical Application
Z A Hewitt, K J Amps and H D Moore
Clin Pharmacol Ther 82: 448-452; advance online publication, August 8, 2007; doi:10.1038/sj.clpt.6100321
Regulation & Use
Practice
Disease Targets and Strategies for the Therapeutic Modulation of Endogenous Neural Stem and Progenitor Cells
S A Goldman
Clin Pharmacol Ther 82: 453-460; advance online publication, August 22, 2007; doi:10.1038/sj.clpt.6100337
Ethics
Finding a Liability-free Space in Which Personalized Medicine can Bloom
B J Evans
Clin Pharmacol Ther 82: 461-465; advance online publication, August 22, 2007; doi:10.1038/sj.clpt.6100335
Public Policy
The Emerging Role of Pharmacogenomics in Biologics
E Lacaná, S Amur, P Mummanneni, H Zhao and F W Frueh
Clin Pharmacol Ther 82: 466-471; advance online publication, August 22, 2007; doi:10.1038/sj.clpt.6100334
